CNS10-NPC-GDNF for the Treatment of ALS

• ClinicalTrials.gov Identifier: NCT02943850
• Recruitment Status: Completed
• First Posted: October 25, 2016
• Last Update Posted: July 15, 2020
• Sponsor: Cedars-Sinai Medical Center
• Collaborator: California Institute for Regenerative Medicine (CIRM)
• Information provided by (Responsible Party): Robert H. Baloh, Cedars-Sinai Medical Center

Study Description

Brief Summary:

The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The growth factor is called glial cell line-derived neurotrophic factor, or GDNF. GDNF is a protein that promotes the survival of many types of neuronal cells. Therefore, the cells are called "CNS10-NPC-GDNF." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, we want to learn if CNS10-NPC-GDNF cells are safe to transplant into the spinal cords of people.

Condition or disease	Intervention/treatment	Phase
Amyotrophic Lateral Sclerosis	Biological: Stem cell (HPC) implantation; Device: Stereotactic surgical device	Phase 1

Detailed Description:

This study will be the first to use a genetically modified progenitor cells to treat a neurodegenerative disease. This is a Phase 1/2a, single-center, blinded (as to side of injection), safety study of two escalating doses of human neural progenitor cells expressing GDNF (CNS10-NPC-GDNF) delivered unilaterally to the lumbar region in ALS subjects with moderate leg involvement.

Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups. Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least two weeks between surgeries.

Specific aims:

Safety, as evaluated by:

• Adverse Events and Serious Adverse Events
• Clinical laboratory assessments, as clinically indicated (hematology, chemistry, immunology)

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 18 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
• Actual Study Start Date: April 1, 2017
• Actual Primary Completion Date: October 18, 2019
• Actual Study Completion Date: October 18, 2019

Arms and Interventions

Arm

Intervention/treatment

Experimental: Stem cell implantation; Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.

Biological: Stem cell (HPC) implantation; All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.; Device: Stereotactic surgical device; A newly developed stereotactic frame is being evaluated as a part of this trial

Outcome Measures

Primary Outcome Measures :

1. Safety evaluated by Adverse Events and Serious Adverse Events, post-operative MRI, and clinical laboratory assessments [ Time Frame: Patients will be followed postoperatively for 12 months ]

   Safety, as evaluated by:

   • Adverse Events and Serious Adverse Events
   • Post-op MRI
   • Clinical laboratory assessments, as clinically indicated (hematology, chemistry, immunology)

Secondary Outcome Measures :

1. Compound Motor Action Potential (CMAP) [ Time Frame: CMAP will be performed 7 times over 15 months ]
   Compound Motor Action Potential - CMAP (Tibialis anterior)
2. Force Generation via ATLIS testing [ Time Frame: ATLIS testing will be performed 7 times over 15 months ]
   Lower extremity Force Generation via ATLIS testing
3. Quantitative Muscle MRI [ Time Frame: Muscle MRI will be performed 6 times over 15 months ]
   Quantitative Muscle MRI of bilateral lower extremities
4. Electrical Impedance Myography (EIM) [ Time Frame: EIM will be performed 7 times over 15 months ]
   Lower Extremity Electrical Impedance Myography (EIM)
5. Assessment of glial cell line derived neurotrophic factor (GDNF) in the cerebral spianl fluid (CSF) [ Time Frame: CSF will be collected at 3 time points over 12 months ]
   Assessment of GDNF in the CSF

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of ALS (Lab-supported Probable, Probable or Definite EI Escorial Criteria)
2. Duration of symptoms ≤ 36 months
3. Progressive weakness in lower extremities, with EMG supported evidence of denervation in both lower extremities.
4. Forced Vital Capacity >60% of predicted normal in supine.
5. Male/Female; Age: 18 and older
6. Able to provide Informed Consent
7. Be geographically accessible to the study site and able to travel to study site for required visits
8. Have caregiver to assist in the transportation and care required by participation in the study
9. Not taking riluzole or on a stable dose for ≥ 30 days
10. For women of child bearing capacity, negative pregnancy test prior to surgery
11. Medically able to undergo thoracolumbar laminectomy or laminoplasty as determined by the site PI and Neurosurgeon
12. Medically able to tolerate the immunosuppression regimen as determined by the site PI

Exclusion Criteria:

1. Using invasive ventilatory assistance
2. Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI

3. Presence of any of the following conditions:

   1. Current drug or alcohol abuse
   2. Any known immunodeficiency syndrome
   3. Unstable medical condition
   4. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening
4. Persons of child bearing capacity not willing to practice birth control
5. Receiving any investigational device/biologic/drug in past 30 days or any previous exposure to stem cell therapy
6. Any condition in the lower extremities which precludes serial strength testing
7. Any condition that the Neurosurgeon feels may pose complications for the surgery
8. Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints

Contacts and Locations

Locations

United States, California

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Sponsors and Collaborators

Cedars-Sinai Medical Center

California Institute for Regenerative Medicine (CIRM)

Investigators

• Principal Investigator: Robert H. Baloh, MD, PhD; Cedars-Sinai Medical Center

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Baloh RH, Johnson JP, Avalos P, Allred P, Svendsen S, Gowing G, Roxas K, Wu A, Donahue B, Osborne S, Lawless G, Shelley B, Wheeler K, Prina C, Fine D, Kendra-Romito T, Stokes H, Manoukian V, Muthukumaran A, Garcia L, Banuelos MG, Godoy M, Bresee C, Yu H, Drazin D, Ross L, Naruse R, Babu H, Macklin EA, Vo A, Elsayegh A, Tourtellotte W, Maya M, Burford M, Diaz F, Patil CG, Lewis RA, Svendsen CN. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. Nat Med. 2022 Sep;28(9):1813-1822. doi: 10.1038/s41591-022-01956-3. Epub 2022 Sep 5.

• Responsible Party: Robert H. Baloh, Director of Neuromuscular Medicine, ALS Program Director, Cedars-Sinai Medical Center
• ClinicalTrials.gov Identifier: NCT02943850
• Other Study ID Numbers: Pro00042350
• First Posted: October 25, 2016
• Last Update Posted: July 15, 2020
• Last Verified: July 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: Yes

Keywords provided by Robert H. Baloh, Cedars-Sinai Medical Center:

stem cells; growth factor; ALS

Additional relevant MeSH terms:

Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Sclerosis; Pathologic Processes; Neurodegenerative Diseases; Nervous System Diseases; Neuromuscular Diseases; Spinal Cord Diseases; Central Nervous System Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Metabolic Diseases